The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide

1990 ◽  
Vol 39 (1) ◽  
pp. 93-95 ◽  
Author(s):  
J. Kallio ◽  
R. Huupponen ◽  
K. Pyykkö
Keyword(s):  
Debrisoquine Oxidation ◽  
Oxidation Phenotype ◽  
The Relationship

Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions

1992 ◽  
Vol 86 (5) ◽  
pp. 364-366 ◽  
Author(s):  
E. Spina ◽  
V. Sturiale ◽  
S. Valvo ◽  
M. Ancione ◽  
A. E. Di Rosa ◽  
...  
Keyword(s):  
Debrisoquine Oxidation ◽  
Oxidation Phenotype

Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population

1991 ◽  
Vol 37 (3) ◽  
pp. 327-332 ◽  
Author(s):  
M Vincent-Viry ◽  
J Muller ◽  
B Fournier ◽  
M M Galteau ◽  
G Siest
Keyword(s):  
Large Population ◽  
Hemoglobin Concentration ◽  
Poor Metabolizers ◽  
Mean Corpuscular Hemoglobin ◽  
Extensive Metabolizers ◽  
Mean Cell Volume ◽  
Factors Affecting ◽  
Blood Constituents ◽  
Debrisoquine Oxidation ◽  
Oxidation Phenotype

Abstract Factors affecting biological variations in debrisoquine-oxidation polymorphism were investigated in a population of 3065 unrelated supposedly healthy Caucasian subjects, ages 35 to 50 years. This population, including 1526 men and 1539 women, was used to determine whether the debrisoquine-oxidation phenotype can be related with environmental factors such as alcohol intake, smoking habits or medication; with morphological variables; or with 22 blood constituents and some pathological states. A single dose of 10 mg of debrisoquine sulfate was administered to determine the oxidation phenotype. A metabolic ratio (debrisoquine/4-hydroxydebrisoquine) of 10.0 defined a poor metabolizer [frequency of 8.2% (SD 1.0%)] in this sample. Dose recoveries of debrisoquine excretion (mean and SD) were 8.9% (11.9%) and 45.1% (32.2%) in extensive and poor metabolizers, respectively. The mean (SD) amount of debrisoquine administered that was excreted in urine as 4-hydroxydebrisoquine was 17.4% (17.3%) in extensive metabolizers and 0.5% (0.9%) in poor metabolizers. The main factors differing significantly between poor and extensive metabolizers were mean cell volume, mean corpuscular hemoglobin concentration, albumin, and ponderal index. No other blood constituents (e.g., cholesterol, glucose) differed between poor and extensive metabolizers. The lack of correlation with most of the variables tested is of interest in clinical trials, because our findings indicate that no subgroups will be required, making selection of subjects easier.

scholarly journals Tiracizine disposition in healthy volunteers with reference to the debrisoquine oxidation phenotype [letter]

1995 ◽  
Vol 40 (3) ◽  
pp. 287-288 ◽  
Author(s):  
A. Berndt ◽  
C. Hoffmann ◽  
K. Richter ◽  
R. Oertel ◽  
A. Vierkant ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Debrisoquine Oxidation ◽  
Oxidation Phenotype

A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype

1995 ◽  
Vol 5 (5) ◽  
pp. 312-317 ◽  
Author(s):  
Kim Brosen ◽  
Sonia M. F. de Morais ◽  
Urs A. Meyer ◽  
Joyce A. Goldstein
Keyword(s):  
Cyp2c19 Genotype ◽  
Oxidation Phenotype ◽  
The Relationship

scholarly journals Debrisoquine oxidation phenotype and susceptibility to lung cancer.

1990 ◽  
Vol 29 (1) ◽  
pp. 101-109 ◽  
Author(s):  
CJ Speirs ◽  
S Murray ◽  
DS Davies ◽  
Biola AF Mabadeje ◽  
AR Boobis
Keyword(s):  
Lung Cancer ◽  
Debrisoquine Oxidation ◽  
Oxidation Phenotype
Sign in / Sign up

Export Citation Format

Share Document